Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Peritoneal Neoplasms 1Genital Neoplasms, Female 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Appendiceal Neoplasms 1

Interventions

Specimen Handling 7Magnetic Resonance Spectroscopy 6Biopsy 6trametinib 2olaparib 2dehydroftorafur 2cobimetinib 2atezolizumab 2Paclitaxel 2Oxaliplatin 2Leucovorin 2Fluorouracil 2Capecitabine 2varlilumab 1tremelimumab 1tofacitinib 1tivozanib 1pevonedistat 1peposertib 1pembrolizumab 1nilotinib 1fludarabine 1durvalumab 1ceralasertib 1binimetinib 1avelumab 1aldesleukin 1Taxes 1Radiofrequency Ablation 1Radiation Dose Hypofractionation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Cholangiocarcinoma × nilotinib × Clear all
NCT05185947 2026-05-29

Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
21 enrolled 21 charts
BreastGastrointestinalGynecologic

Appendiceal Neoplasms, Breast Neoplasms, Genital Neoplasms, Female, Ovarian Neoplasms, Peritoneal Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡